Klotho shares have soared more than 1000% over the past three months on promising results and breakthrough hopes.

US FDA grants orphan drug designation to Klotho Neurosciences’ KLTO-202 to treat amyotrophic lateral sclerosis: New York Saturday, July 12, 2025, 15:00 Hrs [IST] Klotho Neurosci ...

Klotho Neurosciences ( ($KLTO) ) has provided an announcement. On July 10, 2025, Klotho Neurosciences announced that the FDA granted Orphan Drug ...

Klotho is advancing its ALS gene therapy candidate KLTO‑202 to the manufacturing phase, and is planning the first human ...

Investing.com -- Klotho Neurosciences, Inc. (NASDAQ: KLTO) stock surged 22% after the company announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its ...

The FDA’s Orphan Drug Designation offers incentives like seven years of U.S. market exclusivity, tax credits for clinical ...

Boosting Klotho protein levels in mice improves physical and cognitive aging, offering potential for future longevity therapies. A global research effort led by the Institut de Neurociències at the Un ...

With thousands of press releases published each month, it can be difficult to keep up with everything on PR Newswire. To help ...

Get today's Klotho Neuroscience stock news. We cover the latest Klotho Neuroscience headlines and breaking news impacting Klotho Neuroscience stock performance.

Review the current Klotho Neurosciences Inc (KLTO:XNAS) dividend yield and history to decide if KLTO is the best investment for you.

Check out our KLTO stock chart to see a history of performance, current stock value, and a timeline of financial events & indicators for a full analysis today.